Aridis Pharmaceuticals

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARDS and other ETFs, options, and stocks.

About ARDS

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201.

CEO

Vu L. Truong

CEOVu L. Truong

Employees

Employees34

Headquarters

Los Gatos, California

HeadquartersLos Gatos, California

Founded

2003

Founded2003

Employees

Employees34

ARDS Key Statistics

Market cap

18.52M

Market cap18.52M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

38.57K

Average volume38.57K

High today

—

High today—

Low today

—

Low today—

Open price

$0.93

Open price$0.93

Volume

0.00

Volume0.00

52 Week high

$4.34

52 Week high$4.34

52 Week low

$0.6825

52 Week low$0.6825

ARDS Earnings

-$1.94

-$1.29

-$0.65

$0.00

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Estimated

-$0.17 per share

Estimated-$0.17 per share

Actual

-$0.47 per share

Actual-$0.47 per share

Aridis Pharmaceuticals

Why Robinhood?

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. Show more

ARDS Key Statistics

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201.